[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"stock-detail-AYTU":3,"homepage-market-summary":31,"stock-news-AYTU":173},{"ticker":4,"date":5,"profile":6,"dividend":9,"quote":15},"AYTU","2026-10-02",{"name":7,"exchange":8,"sector":9,"industry":10,"description":11,"ceo":9,"employees":12,"headquarters":13,"founded":9,"is_fund":14,"issuer":9,"category":9},"AYTU BioPharma, Inc. Common Stock","Nasdaq",null,"PHARMACEUTICAL PREPARATIONS","Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101\u002Fenzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.","83","Denver, CO",false,{"close":16,"open":17,"high":18,"low":19,"prev_close":20,"change":21,"percent_change":22,"volume":23,"transactions":24,"vwap":25,"high_52w":26,"low_52w":27,"avg_volume_52w":28,"range_52w_percent":29,"record_count":30},2.07,2.08,2.15,2.06,2.09,-0.02,-0.96,15797.008514,243,2.0913,3.07,1.8,65015.53664816733,21.3,4533,{"status":32,"indices":33,"watchlist":77,"sectors":99,"benchmarks":155},"success",[34,42,49,56,63,70],{"symbol":35,"name":36,"price":37,"change":38,"pct_change":39,"is_up":40,"sparkline":41,"date":5},"SPX","S&P 500",7722.72,56.27,0.73,true,"0.0,5.0 2.3,8.0 4.6,10.4 6.9,13.4 9.3,9.1 11.6,11.5 13.9,13.8 16.2,16.0 18.5,10.3 20.8,9.5 23.2,2.0 25.5,2.0 27.8,5.9 30.1,6.0 32.4,3.4 34.7,7.3 37.1,8.2 39.4,9.4 41.7,8.5 44.0,4.8",{"symbol":43,"name":44,"price":45,"change":46,"pct_change":47,"is_up":40,"sparkline":48,"date":5},"NDX","NASDAQ 100",30807.93,306.37,1,"0.0,11.5 2.3,11.7 4.6,12.4 6.9,14.8 9.3,12.8 11.6,14.6 13.9,16.0 16.2,15.9 18.5,12.2 20.8,10.7 23.2,4.4 25.5,2.6 27.8,4.5 30.1,4.5 32.4,3.5 34.7,6.0 37.1,5.5 39.4,5.0 41.7,4.3 44.0,2.0",{"symbol":50,"name":51,"price":52,"change":53,"pct_change":54,"is_up":40,"sparkline":55,"date":5},"DJI","DOW JONES",51177,250,0.49,"0.0,2.0 2.3,5.5 4.6,7.8 6.9,9.5 9.3,6.7 11.6,7.5 13.9,9.4 16.2,12.9 18.5,11.1 20.8,11.7 23.2,9.6 25.5,10.7 27.8,12.6 30.1,13.5 32.4,10.8 34.7,12.8 37.1,13.5 39.4,16.0 41.7,15.9 44.0,14.5",{"symbol":57,"name":58,"price":59,"change":60,"pct_change":61,"is_up":40,"sparkline":62,"date":5},"COMP","NASDAQ Composite",27190.86,319.27,1.19,"0.0,10.2 2.3,11.1 4.6,13.0 6.9,14.9 9.3,12.1 11.6,13.7 13.9,16.0 16.2,16.0 18.5,11.1 20.8,10.0 23.2,3.4 25.5,2.0 27.8,5.4 30.1,5.4 32.4,3.9 34.7,6.7 37.1,6.9 39.4,6.2 41.7,6.1 44.0,2.6",{"symbol":64,"name":65,"price":66,"change":67,"pct_change":68,"is_up":40,"sparkline":69,"date":5},"RUT","RUSSELL 2000",2815.2,25,0.9,"0.0,2.0 2.3,3.0 4.6,6.1 6.9,8.4 9.3,7.5 11.6,8.8 13.9,10.4 16.2,11.3 18.5,10.2 20.8,11.2 23.2,10.1 25.5,8.8 27.8,12.9 30.1,13.1 32.4,12.8 34.7,14.4 37.1,15.1 39.4,16.0 41.7,15.1 44.0,13.2",{"symbol":71,"name":72,"price":73,"change":74,"pct_change":75,"is_up":14,"sparkline":76,"date":5},"VIX","CBOE VIX",15.31,-1.08,-6.59,"0.0,14.8 2.3,10.2 4.6,7.3 6.9,2.0 9.3,9.7 11.6,4.9 13.9,4.5 16.2,2.5 18.5,11.3 20.8,13.7 23.2,13.5 25.5,16.0 27.8,12.3 30.1,10.4 32.4,13.5 34.7,8.8 37.1,8.9 39.4,7.8 41.7,7.6 44.0,11.8",[78,85,92],{"symbol":79,"name":80,"price":81,"change":82,"pct_change":83,"is_up":40,"sparkline":84,"date":5},"NVDA","NVIDIA Corp",233.95,3.09,1.34,"0.0,16.0 7.3,15.3 14.7,9.6 22.0,12.1 29.3,10.3 36.7,6.6 44.0,2.0",{"symbol":86,"name":87,"price":88,"change":89,"pct_change":90,"is_up":40,"sparkline":91,"date":5},"AAPL","Apple Inc",333.69,3.37,1.02,"0.0,8.2 7.3,2.0 14.7,5.2 22.0,16.0 29.3,11.7 36.7,14.9 44.0,10.9",{"symbol":93,"name":94,"price":95,"change":96,"pct_change":97,"is_up":40,"sparkline":98,"date":5},"TSLA","Tesla Inc",370.59,16.48,4.65,"0.0,2.0 7.3,5.3 14.7,13.4 22.0,16.0 29.3,14.9 36.7,15.3 44.0,6.1",[100,105,110,115,120,125,130,135,140,145,150],{"name":101,"etf":102,"change":103,"price":104,"is_up":40},"Technology","XLK",1.01,199.81,{"name":106,"etf":107,"change":108,"price":109,"is_up":40},"Financials","XLF",0.06,53.49,{"name":111,"etf":112,"change":113,"price":114,"is_up":14},"Healthcare","XLV",-0.01,166.18,{"name":116,"etf":117,"change":118,"price":119,"is_up":40},"Consumer Cycl","XLY",1.13,110.04,{"name":121,"etf":122,"change":123,"price":124,"is_up":40},"Consumer Staples","XLP",0.25,80.53,{"name":126,"etf":127,"change":128,"price":129,"is_up":40},"Energy","XLE",0.4,62.95,{"name":131,"etf":132,"change":133,"price":134,"is_up":40},"Industrials","XLI",0.78,169.95,{"name":136,"etf":137,"change":138,"price":139,"is_up":40},"Materials","XLB",0.66,48.86,{"name":141,"etf":142,"change":143,"price":144,"is_up":40},"Real Estate","XLRE",0.32,40.81,{"name":146,"etf":147,"change":148,"price":149,"is_up":40},"Utilities","XLU",0.38,39.83,{"name":151,"etf":152,"change":153,"price":154,"is_up":40},"Comm Services","XLC",0.35,110.32,[156,161,165,169],{"ticker":157,"name":158,"price":159,"change":160,"is_up":40},"SPY","SPDR S&P 500 ETF",769.64,0.74,{"ticker":162,"name":163,"price":164,"change":90,"is_up":40},"QQQ","Invesco QQQ Trust",749.58,{"ticker":166,"name":167,"price":168,"change":54,"is_up":40},"DIA","SPDR Dow Jones ETF",511.1,{"ticker":170,"name":171,"price":172,"change":68,"is_up":40},"IWM","iShares Russell 2000",281.52,{"ticker":4,"count":174,"articles":175},11,[176,182,187,193,198,202,208,214,220,225,230],{"title":177,"link":178,"pubDate":179,"description":180,"source":181},"A depression drug generated $3.9 million in its first full quarter - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiuwFBVV95cUxOb1Rja1ZTOWtXTnRCQW5USmxVSm9hUld0MGpiNUk2SWU0SkFOd3VEeWgyVW5RNE5PbUVxWjZ1RXh6WVRDOC15X09RRDZhblZBZmZBVXpKUlJkM1RNSVROV0s5azcwQlNOR2xqRy1KbXRFMHRnaEhsVzVMQ096aDZfb0Q2LTZ4dDVIVjJ0U09wSEhBcDAzNVI5Z05JdFp1VlBRbS1mYmVFUTlaV1N3b0t5X3A4Y0RvU2Z5VEl3?oc=5","Tue, 22 Sep 2026 07:00:00 GMT","A depression drug generated $3.9 million in its first full quarter Stock Titan","Stock Titan",{"title":183,"link":184,"pubDate":179,"description":185,"source":186},"Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMilwFBVV95cUxOLVpLbXJ1bzNsMS1hd3ZoaXpXTlVGWTQxNHNjc1A0MVhKRTZOazE2cjZRbmhsODZ2VWJudGFIdnZKQzUwcGlTdFk0a1Q1RzI3Q1Jna0Y5WTNKQUM5R3NaZ1hrN0VnV0hJenhZRkV2bzFUS1RZZmNBYTRhT00yQURNUHU5OG9naVZGTkpIU0oxaUNUN28wTFRr?oc=5","Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates Yahoo Finance","Yahoo Finance",{"title":188,"link":189,"pubDate":190,"description":191,"source":192},"Aytu BioPharma Reports $16.1 Million Q4 Revenue as EXXUA Reaches $3.9 Million - Quiver Quantitative","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMitAFBVV95cUxOcm51aXA0SnhMOS02REVod010U0RjdlpScjgwWWQ2Sndjb1FGUXFHeG92Vi1VLUgwaDM5NGdZVnFhSE1mYzRPWHMyeFRsZlcxYkhwQVNldDV0SlFUd3J1RXNlODJqdFBPd2tUNjJBcEY4UTFQLXBiZ2w1Mm4xUGoyVDBFcFQ1MTJxdjB3c3k3cUdQWjNBRGh4UGZSanA1ZjR3TjBDRWJkem43ZW5tcjN5b3A3NG0?oc=5","Tue, 22 Sep 2026 20:10:00 GMT","Aytu BioPharma Reports $16.1 Million Q4 Revenue as EXXUA Reaches $3.9 Million Quiver Quantitative","Quiver Quantitative",{"title":194,"link":195,"pubDate":179,"description":196,"source":197},"AYTU BIOPHARMA, INC FY 2026: Revenue $57.57M, EPS ($1.16) — 10-K Summary - TradingView","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwwFBVV95cUxPRGFDQnR0eFZnWU8yX1g3RkJsVTNMaHZSdXlvVlBRYzZLUW42MFA3eTNkMExGX24tbThodkZJeFd2dFVlNF9mQ0o3VE96TXhQZ2tjN2h1VWR5QWpiME5rUGwwNFRDSUt1bzl6QjM2aERjdzVQZWFHUnhqbjYtUFlrM2dIYUxOdEFUVzY1YTlOYU9TZy1kV2hsTGtDckpfVFgta0ZJTjA5OGM0NTV4b3NXSm9RM3ltdTFfekNnVmtjT3p0R1U?oc=5","AYTU BIOPHARMA, INC FY 2026: Revenue $57.57M, EPS ($1.16) — 10-K Summary TradingView","TradingView",{"title":199,"link":200,"pubDate":179,"description":201,"source":181},"EXXUA prescriptions jump as Aytu BioPharma (AYTU) posts Q4 and full-year results - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiqwFBVV95cUxQNnhUWmFBR1ZhaHR3eFFseUJrbmdmaEtWclV0ZjdRTWFrbDdGa1hETFJLQ0JHakpSSkpOSVluZE9nVW1JMk91VWc2UUgxV1J3eEdOMDJXbDJyRzNUNWN3OGU2aHpwUWdGei1tYlB5ZFFsTGl4YlZ4Rm5xQ2NYeXJvalpWVW9YUjZCUEhxUGRkSTZ3cTRDUGo2a19YTTc1b2RNWHRiUkxkR2E1cE0?oc=5","EXXUA prescriptions jump as Aytu BioPharma (AYTU) posts Q4 and full-year results Stock Titan",{"title":203,"link":204,"pubDate":205,"description":206,"source":207},"Aytu BioScience Earnings Call Highlights EXXUA Momentum - The Globe and Mail","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi1wFBVV95cUxNVzhJRVRHWlI0WXN0MWw1dGlNNnNsQUh6QWJDTDhPUzMwQzFVNlNBaUZTdzluRWpabkNkVmh0Tlp6dDJ2RW1XaXNyeDlCZXJfdERyU1pEOFFXNVQ3MmNGWG1QSVpmY1hkSGM5WnFjWHVNejBDd1kyLW1JSHpwVWNEQXI0QUdPOEdOdmhiZGRtb2o2cmZyZURHTUdEdXJ5a1piczFFRnRfWl9MbzBIcmZkRGwweTBERlVuWXoyMllEdEMzbmJuTkwzQ3JBYWo5bHk5RkFlNWR6VQ?oc=5","Wed, 30 Sep 2026 00:24:00 GMT","Aytu BioScience Earnings Call Highlights EXXUA Momentum The Globe and Mail","The Globe and Mail",{"title":209,"link":210,"pubDate":211,"description":212,"source":213},"Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi5gFBVV95cUxNaXo1NFprTURTRTU4b1RmOWFjbVFoS0N3R0xtemF5Zkw4YVdVN0pGdlpzelRWaTBmdEVwcW03N3pnMGh6N196UElEalN6c0FjcGRVUFJRMEpzcjAyR0haV3ZvdjdUX0V4elZhcWhXSlhpU0JjNktaajdEelc2ak15c1llb0Zmc0xpVEtQWWxFNzFmZ0w3eTUzQmpmQTVfUmdMRE03UnJSXzNMNlUzQm9yQTZwMWdmU3JOdXI2QnVSZXNxYkd0Q2VSU3A3dHlSakstQVFqVnhkM2lJYmNmcFBVTWJNaWNYdw?oc=5","Wed, 30 Sep 2026 12:22:08 GMT","Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday Benzinga","Benzinga",{"title":215,"link":216,"pubDate":217,"description":218,"source":219},"Aytu BioPharma beats Q4 estimates on EXXUA launch momentum, shares rise 4% - Investing.com UK","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMizgFBVV95cUxPV2ZHbFRpcy1nR3E2OF9EcVJkRXdPeHFyeXJpUFJVMHhZWm9CZjljRDFoUlpCRTAxa1BsYkdRWExnb0VSbC1DLXB5Q29wT3pPNk5Wck14ZGVadDZyLXl4NmRIQ0QweGV2aVBmSG9GNXNTTjdKcFl6ZGpxbnVDSW43OG5fRVh4SWw1ZDR4N0E4V1kwR0VhOFNYRGEwUFVFUjBlTHFZMGxoc19hb0taSGlyVnlRZG1yN2Jocm1JWmtMTjZhVDJEUU1wbks4V0l4QQ?oc=5","Tue, 22 Sep 2026 20:46:00 GMT","Aytu BioPharma beats Q4 estimates on EXXUA launch momentum, shares rise 4% Investing.com UK","Investing.com UK",{"title":221,"link":222,"pubDate":223,"description":224,"source":197},"Ascendiant Capital maintains Buy rating on Aytu BioPharma, $15 price target - TradingView","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi0AFBVV95cUxORFlmN0J5cFRURTU0RVFXZGxNRHVWekg2VzJXUFJxSTI1cjh6c2VSSlZfN09vSlNEZDZSU3pfNXNESWt4OWhOMTkwaDBDQ3NvZE1faEZGZ01rQmFOdEs0ZUJLeHZLcGZjOFI5aGplU1dqaGtqajhSalNmT1JsTzU5RHhUcVZLTU9OTFdILS1fOVhsZ3pHeEZISGExVnhZYmswYW9LZlZXb0tYSjFYRmcyckhqdERkMmRQeVUyY1JoRzRFa0hpa3BOanpEUTViOEZH?oc=5","Wed, 30 Sep 2026 09:56:38 GMT","Ascendiant Capital maintains Buy rating on Aytu BioPharma, $15 price target TradingView",{"title":226,"link":227,"pubDate":179,"description":228,"source":229},"Aytu BioPharma Q4FY26 Results: Sales up 6.4% YoY to $16.1M - scanx.trade","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMipAFBVV95cUxQSldXY0djQWp4clVzR1R6a0xjR2FEaFBTUWNRZGFyMWJIZnBnd3NsRXpBaFo2bTFtLUFJSXdCWTNqUDV3U2VBc0dqMDZvejZ5S1lzUDhXTlVnMnhYVUFRc3VmNWlEVm1XWEVmWWRKSjNtZHVLT0hSbmk4TmFELW1kZXA5LXJ3bHhSblU3TzlObGlBMWRwZnVZbWQ1OGxPcWRmV2hlUA?oc=5","Aytu BioPharma Q4FY26 Results: Sales up 6.4% YoY to $16.1M scanx.trade","scanx.trade",{"title":231,"link":232,"pubDate":233,"description":234,"source":235},"Earnings call transcript: Aytu BioPharma tops Q4 2026 revenue forecast By Investing.com - Investing.com Canada","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiygFBVV95cUxOOUpqcHNfOEZKS0xxb2ljd29fUlB4Q0hCYVY1RW1uTW9NTkdRemRoRk81ZFFvbnRfRk45QkdJZm10T09MY3NNSi00QUY4Z2lHc2Jqdlh3Q3Z4ZDF4WFFpVGhwc2tUVzM4R2tOSF9JSDZCTzJhNG16aUtfMENtWlREX0FWcml1VjNfd0FOWERsbXM2VTE2VzhteFZicVdjVGJ4bmthcE1zakhpRkpoVHJpWXN0RWJWbVRHcDBHUkVuZkxaamZEOGphT0hB?oc=5","Tue, 22 Sep 2026 22:45:24 GMT","Earnings call transcript: Aytu BioPharma tops Q4 2026 revenue forecast By Investing.com Investing.com Canada","Investing.com Canada"]